ADAPTIVE BIOTECHNOLOGIES CORPORATION Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $429.00 thousand as of 2022-09-30, per its 10-Q filed 2022-11-03.
Discontinued › Notes › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2022-11-03
- 2022-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $429.00K.
- 2022-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $857.00K.
- 2022-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $1.28M.
- 2021-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $429.00K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2022-09-30 | $429.00K 10-Q · filed 2022-11-03 |
| 2022-06-30 | $857.00K 10-Q · filed 2022-08-03 |
| 2022-03-31 | $1.28M 10-Q · filed 2022-05-04 |
| 2021-09-30 | $429.00K 10-Q · filed 2021-11-03 |
| 2021-06-30 | $857.00K 10-Q · filed 2021-08-04 |
| 2021-03-31 | $1.28M 10-Q · filed 2021-05-05 |
| 2020-09-30 | $428.00K 10-Q · filed 2020-11-10 |
| 2020-06-30 | $856.00K 10-Q · filed 2020-08-10 |
| 2020-03-31 | $1.28M 10-Q · filed 2020-05-12 |
| 2019-12-31 | $1.70M 10-K · filed 2020-02-26 |
| 2019-09-30 | $428.00K 10-Q · filed 2019-11-12 |
| 2019-06-30 | $856.00K 10-Q · filed 2019-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |